Sensei Biotherapeutics hosts SNS-101 KOL event; no new data disclosed

Sensei Biotherapeutics, Inc.

Virtual key opinion leader event on June 27, 2023, featuring SNS-101 for solid tumors.
Presenters include CEO John Celebi, CSO Dr. Edward van der Horst, CMO Ron Weitzman.
Guest speaker: Dr. James Gulley, Co-Director, Center for Immuno-Oncology at NCI.
Event is forward-looking; no clinical results or financial guidance provided.
SNS-101 positioned as potential transformative treatment; no material milestones announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.